-
Je něco špatně v tomto záznamu ?
Nebulization and In Vitro Upper Airway Deposition of Liposomal Carrier Systems
O. Mišík, J. Kejíková, O. Cejpek, M. Malý, A. Jugl, M. Bělka, F. Mravec, F. Lízal
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- 1,2-dipalmitoylfosfatidylcholin MeSH
- aerosoly MeSH
- aplikace inhalační MeSH
- bronchodilatancia * MeSH
- cholesterol MeSH
- design vybavení MeSH
- lékové transportní systémy MeSH
- lidé MeSH
- liposomy MeSH
- nebulizátory a vaporizátory MeSH
- trachea * MeSH
- velikost částic MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Liposomal carrier systems have emerged as a promising technology for pulmonary drug delivery. This study focuses on two selected liposomal systems, namely, dipalmitoylphosphatidylcholine stabilized by phosphatidic acid and cholesterol (DPPC-PA-Chol) and dipalmitoylphosphatidylcholine stabilized by polyethylene glycol and cholesterol (DPPC-PEG-Chol). First, the research investigates the stability of these liposomal systems during the atomization process using different kinds of nebulizers (air-jet, vibrating mesh, and ultrasonic). The study further explores the aerodynamic particle size distribution of the aerosol generated by the nebulizers. The nebulizer that demonstrated optimal stability and particle size was selected for more detailed investigation, including Andersen cascade impactor measurements, an assessment of the influence of flow rate and breathing profiles on aerosol particle size, and an in vitro deposition study on a realistic replica of the upper airways. The most suitable combination of a nebulizer and liposomal system was DPPC-PA-Chol nebulized by a Pari LC Sprint Star in terms of stability and particle size. The influence of the inspiration flow rate on the particle size was not very strong but was not negligible either (decrease of Dv50 by 1.34 μm with the flow rate increase from 8 to 60 L/min). A similar effect was observed for realistic transient inhalation. According to the in vitro deposition measurement, approximately 90% and 70% of the aerosol penetrated downstream of the trachea using the stationary flow rate and the realistic breathing profile, respectively. These data provide an image of the potential applicability of liposomal carrier systems for nebulizer therapy. Regional lung drug deposition is patient-specific; therefore, deposition results might vary for different airway geometries. However, deposition measurement with realistic boundary conditions (airway geometry, breathing profile) brings a more realistic image of the drug delivery by the selected technology. Our results show how much data from cascade impactor testing or estimates from the fine fraction concept differ from those of a more realistic case.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24014447
- 003
- CZ-PrNML
- 005
- 20240905133927.0
- 007
- ta
- 008
- 240725s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.molpharmaceut.3c01146 $2 doi
- 035 __
- $a (PubMed)38466817
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Mišík, Ondrej $u Department of Thermodynamics and Environmental Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic $1 https://orcid.org/0000000346835145
- 245 10
- $a Nebulization and In Vitro Upper Airway Deposition of Liposomal Carrier Systems / $c O. Mišík, J. Kejíková, O. Cejpek, M. Malý, A. Jugl, M. Bělka, F. Mravec, F. Lízal
- 520 9_
- $a Liposomal carrier systems have emerged as a promising technology for pulmonary drug delivery. This study focuses on two selected liposomal systems, namely, dipalmitoylphosphatidylcholine stabilized by phosphatidic acid and cholesterol (DPPC-PA-Chol) and dipalmitoylphosphatidylcholine stabilized by polyethylene glycol and cholesterol (DPPC-PEG-Chol). First, the research investigates the stability of these liposomal systems during the atomization process using different kinds of nebulizers (air-jet, vibrating mesh, and ultrasonic). The study further explores the aerodynamic particle size distribution of the aerosol generated by the nebulizers. The nebulizer that demonstrated optimal stability and particle size was selected for more detailed investigation, including Andersen cascade impactor measurements, an assessment of the influence of flow rate and breathing profiles on aerosol particle size, and an in vitro deposition study on a realistic replica of the upper airways. The most suitable combination of a nebulizer and liposomal system was DPPC-PA-Chol nebulized by a Pari LC Sprint Star in terms of stability and particle size. The influence of the inspiration flow rate on the particle size was not very strong but was not negligible either (decrease of Dv50 by 1.34 μm with the flow rate increase from 8 to 60 L/min). A similar effect was observed for realistic transient inhalation. According to the in vitro deposition measurement, approximately 90% and 70% of the aerosol penetrated downstream of the trachea using the stationary flow rate and the realistic breathing profile, respectively. These data provide an image of the potential applicability of liposomal carrier systems for nebulizer therapy. Regional lung drug deposition is patient-specific; therefore, deposition results might vary for different airway geometries. However, deposition measurement with realistic boundary conditions (airway geometry, breathing profile) brings a more realistic image of the drug delivery by the selected technology. Our results show how much data from cascade impactor testing or estimates from the fine fraction concept differ from those of a more realistic case.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a bronchodilatancia $7 D001993
- 650 12
- $a trachea $7 D014132
- 650 _2
- $a 1,2-dipalmitoylfosfatidylcholin $7 D015060
- 650 _2
- $a nebulizátory a vaporizátory $7 D009330
- 650 _2
- $a liposomy $7 D008081
- 650 _2
- $a aerosoly $7 D000336
- 650 _2
- $a aplikace inhalační $7 D000280
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a cholesterol $7 D002784
- 650 _2
- $a velikost částic $7 D010316
- 650 _2
- $a design vybavení $7 D004867
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kejíková, Jana $u Institute of Physical and Applied Chemistry, Faculty of Chemistry, Brno University of Technology, Purkyňova 464/118, Královo Pole, 612 00 Brno, Czech Republic
- 700 1_
- $a Cejpek, Ondřej $u Department of Thermodynamics and Environmental Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic
- 700 1_
- $a Malý, Milan $u Department of Thermodynamics and Environmental Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic
- 700 1_
- $a Jugl, Adam $u Institute of Physical and Applied Chemistry, Faculty of Chemistry, Brno University of Technology, Purkyňova 464/118, Královo Pole, 612 00 Brno, Czech Republic $1 https://orcid.org/0000000306022334 $7 ola20211132987
- 700 1_
- $a Bělka, Miloslav $u Department of Thermodynamics and Environmental Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic
- 700 1_
- $a Mravec, Filip $u Institute of Physical and Applied Chemistry, Faculty of Chemistry, Brno University of Technology, Purkyňova 464/118, Královo Pole, 612 00 Brno, Czech Republic $1 https://orcid.org/0000000161144751
- 700 1_
- $a Lízal, František $u Department of Thermodynamics and Environmental Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technicka 2896/2, 616 69 Brno, Czech Republic
- 773 0_
- $w MED00008279 $t Molecular pharmaceutics $x 1543-8392 $g Roč. 21, č. 4 (2024), s. 1848-1860
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38466817 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20240905133921 $b ABA008
- 999 __
- $a ok $b bmc $g 2143918 $s 1226313
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 21 $c 4 $d 1848-1860 $e 20240311 $i 1543-8392 $m Molecular pharmaceutics $n Mol Pharm $x MED00008279
- LZP __
- $a Pubmed-20240725